Net (Loss) Income per Share - Basic and Diluted (Details) - shares	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average unvested restricted common stock that has been issued and is subject to forfeiture (in shares)	45,363	24,094
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	6,947,783	5,872,252
Common Stock Warrants, Excluding Pre-funded Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	6,127,872	5,661,699
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	161,276	89,338
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	45,363	24,094
Preferred Stock, as Converted into Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	42,426	42,426
Common Stock Reserved for Future Issuance
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from the calculation of net loss per share (in shares)	570,846	54,695

KIORA PHARMACEUTICALS INC 10-Q